Abstract | PURPOSE: MATERIALS AND METHODS: RESULTS: The 5-year locoregional control rates were 50% and 35% in the two groups with or without IOERT, respectively (p=0.04). Two patients had recurrence within the IOERT field in the EBRT+IOERT group and 14 patients recurred in the same area in the EBRT group (p=0.02). Multivariate analyses revealed that adjuvant IOERT was an independent prognosticator for both local-regional control (p=0.02) and disease-free survival (p=0.05). G3/4 late toxicity was observed in 5 patients in the EBRT+IOERT group, but none in the EBRT group (p=0.02). CONCLUSIONS: Higher radiation dose may contribute to the improvement of local control, especially in the field encompassed by IOERT. The addition of IOERT to surgery and adjuvant chemoradiation deserves further investigation in a randomized trial.
|
Authors | Qing Zhang, Jeremy Tey, Lihua Peng, Zhe Yang, Fei Xiong, Ruiyao Jiang, Taifu Liu, Shen Fu, Jiade J Lu |
Journal | Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
(Radiother Oncol)
Vol. 102
Issue 1
Pg. 51-5
(Jan 2012)
ISSN: 1879-0887 [Electronic] Ireland |
PMID | 22178689
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2011 Elsevier Ireland Ltd. All rights reserved. |
Chemical References |
- Taxoids
- Docetaxel
- Cisplatin
- Leucovorin
- Fluorouracil
|
Topics |
- Adenocarcinoma
(drug therapy, pathology, radiotherapy, surgery)
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Chemotherapy, Adjuvant
- Chi-Square Distribution
- Cisplatin
(administration & dosage)
- Docetaxel
- Female
- Fluorouracil
(administration & dosage)
- Gastrectomy
(methods)
- Humans
- Intraoperative Care
- Leucovorin
(administration & dosage)
- Male
- Middle Aged
- Neoplasm Grading
- Neoplasm Recurrence, Local
- Neoplasm Staging
- Postoperative Care
- Prognosis
- Radiotherapy Dosage
- Radiotherapy, Adjuvant
- Stomach Neoplasms
(drug therapy, pathology, radiotherapy, surgery)
- Survival Rate
- Taxoids
(administration & dosage)
- Treatment Outcome
|